Allos Therapeutics — Q2 2011 Earnings Presentation
24 slides from Allos Therapeutics's earnings presentation, Jul 26, 2011
Slide 1: 2Q 2011 Financial Results
2Q 2011 Financial Results JULY 26, 2011 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements 2 Forward-looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, includin
Slide 3: Important Merger Information and Where to Find It
Important Merger Information and Additional Information and Where to Find It This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. The proposed merger between AMAG and Allos will be submitted to the re
Slide 4: Agenda
Agenda Opening Remarks – Brian Pereira, CEO Commercial – Gary Zieziula, Chief Commercial Officer Merger with Allos Therapeutics – Brian Pereira, CEO Q&A Session 4
Slide 5: Opening Remarks
OPENING REMARKS Brian Pereira, Chief Executive Officer 5
Slide 6: Business Update – 2Q 2011
Business Update – 2Q 2011 Strong product revenue growth $15.4 million in total revenues, including $12.8 million in Feraheme net product revenues 24% increase in provider demand compared to 1Q11 Continued progress on market expansion for Feraheme European and Canadian regulatory review progressing w
Slide 7: Commercial
COMMERCIAL Gary Zieziula, Chief Commercial Officer 7
Slide 8: 2Q11 Commercial Update
2Q11 Commercial Update $15.4 million in total revenues, including $12.8 million in Feraheme net product revenues Provider demand increased 24% quarter-over-quarter Growth in all target segments Level playing field for non-dialysis CKD product labels Feraheme label update June 2011 Decreased observat
Slide 9: 24% Demand Growth Quarter-over-Quarter
9 24% Demand Growth Quarter-over-Quarter Sources: IMS Health Monthly DDD derived grams and launch incentive program utilization, excluding returns by launch incentive program customers. Feraheme Grams
Slide 10: 29% Increase in Hematology/Oncology Provider Demand
29% Increase in Hematology/Oncology Provider Demand Feraheme Grams 10 Market Share (percent) Sources: IMS Health Monthly DDD derived grams
Slide 11: 33% Increase in Hospital Provider Demand
33% Increase in Hospital Provider Demand Feraheme Grams 11 Market Share (percent) Sources: IMS Health Monthly DDD derived grams
Slide 12: 5% Increase in Nephrology Provider Demand
5% Increase in Nephrology Provider Demand 12 Feraheme Grams Market Share (percent) Sources: IMS Health Monthly DDD derived grams
Slide 13: 2Q 2011 Feraheme Commercial Summary
2Q 2011 Feraheme Commercial Summary Provider demand increased 24% quarter-over quarter Momentum building in hematology/oncology clinics and hospitals – high-volume sites of care where non-dialysis CKD patients receive IV iron Label changes to Feraheme and Venofer create a level playing field 13
Slide 14: Commercial Rationale of Allos Merger
COMMERCIAL RATIONALE of ALLOS MERGER Gary Zieziula, Chief Commercial Officer 14
Slide 15: Strong Strategic Commercial Fit
Strong Strategic Commercial Fit Improved Access, Reach & Promotional Activity for Both Brands Common call points Hematology/oncology clinics, academic and community hospitals GPOs KOLs Increases account access & penetration 100% coverage of target accounts for both brands1 Increases share of voice f
Slide 16: Favorable Market Dynamics of Merger
Favorable Market Dynamics of Merger 1.SDI CKD / IDA & PTCL Analysis, based on ICD-9 code data 2010 Data (Raw physician count, n = 2,943) 2. Internal Allos target list analysis ~83% of community Hem / Onc physicians that treat PTCL also treat IDA in CKD1 ~75% target Feraheme accounts overlap with Fol
Slide 17: Allos Merger
ALLOS MERGER Brian Pereira, Chief Executive Officer 17
Slide 18: Strategic Rationale of Merger
Strategic Rationale of Merger Based on conservative cases, deal provides $20 million in incremental cash flows in 2013; increasing to approximately $50M by 2016 Overlapping call points in hematology/oncology and hospitals provides enhanced access for Feraheme Largest non-dialysis CKD market segments
Slide 19: NewCo Conservative Revenue Expectations
NewCo Conservative Revenue Expectations Conservative case combined net product revenues in 2013 of at least $125 million ~$70 million of Feraheme CKD net product revenues (US and EU) ~$55 million of Folotyn US net product revenues Assumptions: Current US labels/indications for Folotyn and Feraheme E
Slide 20: NewCo Expense Expectations
NewCo Expense Expectations Companies had estimated $215 - $230 million in combined cash operating expenses for full year 2011 (excluding COGS) NewCo cash operating expenses in 2013 expected to be no greater than $120 million (excluding COGS) Synergies of $55 to $60 million annually, majority achieve
Slide 21: NewCo Conservative Cash Expectations
NewCo Conservative Cash Expectations Management is committed to driving NewCo to cash flow breakeven by year-end 2013, earlier than with Feraheme alone Approximately $20 million in incremental annual cash flow generated by deal in 2013, increasing to at least $50 million by 2016 NewCo cash position
Slide 22: Potential Upside to Conservative Case
Potential Upside to Conservative Case Revenues Feraheme CKD and Folotyn revenue synergies through expanded share of voice and access Feraheme sales from US IDA approval/launch Folotyn sales from label expansions (first-line PTCL and rrCTCL) Folotyn use derived from results of investigator sponsored
Slide 23: Focused on Building Long-term Value for Shareholders
Focused on Building Long-term Value for Shareholders We believe the merger with Allos Therapeutics Expands access to hematology/oncology for Feraheme in CKD and broad IDA indications Leverages existing commercial infrastructure and cost-base in hematology/oncology space Spreads public company costs
Slide 24: Q&A
Q&A 24